DAPK enhances DDX20 protein stability via suppression of TRIM25-mediated ubiquitination-based DDX20 degradation
Rattachement africain : cn, il. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
We have previously found that the DAPK-DDX20 signaling axis exerts an anti-cancer activity in hepatocellular carcinoma (HCC) by inhibiting the GTPase activity of CDC42, thereby reducing the invasive and migratory capabilities of cancer cells without affecting cell proliferation. DDX20 serves as an intermediate protein regulated by DAPK in the control of CDC42. Specifically, DAPK enhances DDX20 protein levels by suppressing DDX20 degradation. However, the mechanism underlying DAPK regulation of DDX20 remains unclear. In the current study, we discovered that DDX20 is degraded through the ubiquitin-proteasome pathway and identified TRIM25 as the E3 ubiquitin ligase of DDX20. TRIM25 mediates the proteasomal degradation of DDX20 by binding to, and ubiquitinating the 1-244 amino acid region of DDX20. Moreover, DAPK interacts with this 1-244 segment of DDX20, inhibiting its ubiquitination and enhancing its stability, despite the lack of direct physical interaction between DAPK and the 1-244 region of DDX20. Remarkably, DAPK, TRIM25, and DDX20 form a ternary protein complex in cells, and knockdown of TRIM25 leads to a reduction in the cellular levels of the binary DAPK-DDX20 complex, suggesting that TRIM25 acts as an important intermediate protein linking DAPK and DDX20. TRIM25 functions as an oncogene in liver cancer, as shRNA-mediated silencing of TRIM25 inhibits cell migration and invasion. Therefore, these novel findings of the interaction among these three proteins not only enhances our knowledge of the downstream molecular network of DAPK and its possible role in the development of HCC, but also provides potential druggable targets for the future development of novel anticancer drug therapeutics.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- DAPK enhances DDX20 protein stability via suppression of TRIM25-mediated ubiquitination-based DDX20 degradation
- Date Crossref
- 18/11/2024
- Éditeur
- Springer Science and Business Media LLC
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
Fujian University of Traditional Chinese Medicine pays non établi dans la noticeUniversité ou école supérieure
-
Ganzhou People's Hospital pays non établi dans la noticeÉtablissement de santé
-
Fujian Normal University pays non établi dans la noticeUniversité ou école supérieure
-
Fuzhou Second Hospital pays non établi dans la noticeÉtablissement de santé
-
Technion – Israel Institute of Technology pays non établi dans la noticeUniversité ou école supérieure
-
College of Integrative Medicine pays non établi dans la noticeUniversité ou école supérieure
-
the Affiliated Ganzhou Hospital of Nanchang University Ganzhou Key Laboratory of Molecular Medicine pays non établi dans la noticeUniversité ou école supérieure
-
College of Life Sciences pays non établi dans la noticeUniversité ou école supérieure
-
Department of Central Laboratory pays non établi dans la noticeStructure de recherche
-
Faculty of Biology The Fred Wyszkowski Cancer Research Laboratory pays non établi dans la noticeUniversité ou école supérieure
Fujian University of Traditional Chinese Medicine, Ganzhou People's Hospital et Fujian Normal University, avec 7 autres affiliations.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.